Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data
Crossref DOI link: https://doi.org/10.1007/s40744-019-00183-6
Published Online: 2019-11-21
Published Print: 2020-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Emery, Paul
Furst, Daniel E.
Kirchner, Petra
Melega, Simone
Lacey, Stuart
Lehane, Patricia B.
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd.
Text and Data Mining valid from 2019-11-21
Version of Record valid from 2019-11-21
Article History
Received: 3 September 2019
First Online: 21 November 2019